![Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/0ed07044-02d7-4c0e-95a7-b9a3d949e5df/gr1.jpg)
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine
1-min ID consult on X: "【The 5 Ds of outpatient antibiotic stewardship for UTI】 Let's review 5Ds model of stewardship for UTI ・Diagnosis ・Drug ・Dose ・Duration ・De-escalation Level: Basic Importance #IDTwitter #
![Variation of Surface Dose (D s ) Surface Dose (Ds) The curve showed... | Download Scientific Diagram Variation of Surface Dose (D s ) Surface Dose (Ds) The curve showed... | Download Scientific Diagram](https://www.researchgate.net/publication/342497715/figure/fig1/AS:907034312597504@1593265240347/Variation-of-Surface-Dose-D-s-Surface-Dose-Ds-The-curve-showed-that-the-surface-dose.png)
Variation of Surface Dose (D s ) Surface Dose (Ds) The curve showed... | Download Scientific Diagram
![Dose‐normalized plasma pharmacokinetic parameters of DS‐1211 (a) Cmax... | Download Scientific Diagram Dose‐normalized plasma pharmacokinetic parameters of DS‐1211 (a) Cmax... | Download Scientific Diagram](https://www.researchgate.net/publication/357788653/figure/fig2/AS:11431281179882722@1691411946716/Dose-normalized-plasma-pharmacokinetic-parameters-of-DS-1211-a-Cmax-of-single-ascending.png)
Dose‐normalized plasma pharmacokinetic parameters of DS‐1211 (a) Cmax... | Download Scientific Diagram
![Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/20656edb-004d-431e-af4b-0e09c258f296/gr1.gif)